FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

The U.S. Food and Drug Administration approved on Tuesday Amgen's (AMGN.O) Bkemv, the first biosimilar to AstraZeneca's (AZN.L), rare blood disorder treatment Soliris.
Amgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex biological drugs.